SCM
IMGN

Stonebridge Capital Management’s Immunogen Inc IMGN Stock Holding History

Stonebridge Capital Management’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-24,685
Closed -$262K – 195
2014
Q3 		$262K Sell
24,685
-22,215
-47% -$251K 0.1% 150
2014
Q2 		$556K Buy
46,900
+20,810
+80% +$261K 0.21% 100
2014
Q1 		$389K Buy
26,090
+3,940
+18% +$62.1K 0.16% 127
2013
Q4 		$325K Buy
22,150
+2,400
+12% +$36.9K 0.13% 136
2013
Q3 		$336K Buy
19,750
+8,125
+70% +$143K 0.15% 129
2013
Q2 		$193K Buy
+11,625
New +$188K 0.09% 160

Other funds holding IMGN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Stonebridge Capital Management's IMGN Position: Q4 2014 in Review

Stonebridge Capital Management sold out of Immunogen Inc (IMGN) in Q4 2014, closing a stake of 24,685 shares — an estimated $262K sold.

Stonebridge Capital Management first reported a position in IMGN in Q2 2013 and held it in 6 quarters. The position peaked at $556K in Q2 2014. 131 funds tracked by Wall St. Rank hold IMGN as of Q4 2014.

  • Stonebridge Capital Management reported no remaining Immunogen Inc position as of Q4 2014 after selling out during the quarter.
  • Stonebridge Capital Management sold 24,685 Immunogen Inc shares in Q4 2014, an estimated $262K.
  • Stonebridge Capital Management first reported a position in Immunogen Inc in Q2 2013 and held it in 6 quarters.
  • Stonebridge Capital Management's Immunogen Inc position peaked at $556K in Q2 2014.
  • 131 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2014.

Based on Stonebridge Capital Management's 13F filing for Q4 2014, filed 5 Feb 2015.